EXEL Stock Analysis: Exelixis | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.540m USD | 12M Return: 33.2% | US30161Q1040 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 140M
EPS Trend: 95.0%
Qual. Beats: 0
Rev. Trend: 96.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exelixis, Inc. is a U.S.-based oncology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its marketed portfolio is anchored by cabozantinib, the active ingredient in both CABOMETYX (advanced renal cell carcinoma) and COMETRIQ (metastatic medullary thyroid cancer), and also includes COTELLIC, a MEK inhibitor used in combination therapy for advanced melanoma. Beyond oncology, the company markets MINNEBRO, an oral mineralocorticoid receptor blocker approved for hypertension in Japan through a regional partner.
The company is advancing a pipeline of experimental oncology candidates, including kinase inhibitors (zanzalintinib), a USP1 inhibitor for BRCA-mutated tumors (XL309), and several antibody-drug conjugates and bispecific antibodies (XB010, XB628, XB371). Exelixis supplements its internal R&D with an extensive network of research collaborations and license agreements with major pharmaceutical and biotechnology partners, including Ipsen, Takeda, Roche/Genentech, Bristol-Myers Squibb, and Daiichi Sankyo-a licensing-heavy model common among biotech firms seeking to extend geographic reach and share development risk. Incorporated in 1994 and headquartered in Alameda, California, Exelixis operates within the biotechnology sub-industry of the broader health care sector.
- CABOMETYX sales growth drives revenue and label expansions
- Zanzalintinib and ADC pipeline catalysts advance through clinical trials
- Ipsen Takeda partnerships deliver ex-US royalty revenue
| Net Income: 860.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.47 > 0.02 and ΔFCF/TA 20.35 > 1.0 |
| NWC/Revenue: 36.49% < 20% (prev 37.88%; Δ -1.39% < -1%) |
| CFO/TA 0.47 > 3% & CFO 1.18b > Net Income 860.6m |
| Net Debt (-673.5m) to EBITDA (999.8m): -0.67 < 3 |
| Current Ratio: 3.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (259.7m) vs 12m ago -8.69% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 94.19% > 50% (prev 83.27%; Δ 10.92% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.36 (Total Current Assets 1.25b - Total Current Liabilities 361.9m) / Total Assets 2.49b |
| B: -0.11 (Retained Earnings -262.5m / Total Assets 2.49b) |
| C: 0.38 (EBIT TTM 971.5m / Avg Total Assets 2.59b) |
| D: 2.83 (Book Value of Equity 1.84b / Total Liabilities 650.5m) |
| Altman-Z'' = 7.50 = AAA |
| DSRI: 1.05 (Receivables 334.6m/292.4m, Revenue 2.44b/2.23b) |
| GMI: 1.00 (GM 96.59% / 96.48%) |
| AQI: 0.90 (AQ_t 0.36 / AQ_t-1 0.40) |
| SGI: 1.09 (Revenue 2.44b / 2.23b) |
| TATA: -0.13 (NI 860.6m - CFO 1.18b) / TA 2.49b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of August 15, 2026, the stock is trading at USD 51.24 with a total of 1,795,328 shares traded. Over the past week, the price has changed by -5.23%, over one month by -8.12%, over three months by +0.27% and over the past year by +33.19%.
Current recommended Stop Loss: 49.10 (which is 4.2% or 1.2 ATR below the current price).
Exelixis has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy EXEL.
- StrongBuy: 9
- Buy: 1
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 52.9 | 3.3% |
P/E Trailing = 15.9151
P/E Forward = 16.7224
P/S = 5.148
P/B = 7.1213
P/EG = 2.2685
Revenue TTM = 2.44b USD
EBIT TTM = 971.5m USD
EBITDA TTM = 999.8m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 165.9m USD (from shortLongTermDebtTotal, last quarter) (leases 165.9m already included)
Net Debt = -673.5m USD (calculated: Debt 165.9m - CCE 839.4m)
Enterprise Value = 11.9b USD (12.5b + Debt 165.9m - CCE 839.4m)
Interest Coverage Ratio = unknown (Ebit TTM 971.5m / Interest Expense TTM 0.0)
EV/FCF = 10.05x (Enterprise Value 11.9b / FCF TTM 1.18b)
FCF Yield = 9.95% (FCF TTM 1.18b / Enterprise Value 11.9b)
FCF Margin = 48.47% (FCF TTM 1.18b / Revenue TTM 2.44b)
Net Margin = 35.33% (Net Income TTM 860.6m / Revenue TTM 2.44b)
Gross Margin = unknown ((Revenue TTM 2.44b - Cost of Revenue TTM 85.7m) / Revenue TTM)
Tobins Q-Ratio = 4.76 (Enterprise Value 11.9b / Total Assets 2.49b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 165.9m)
Taxrate = 16.89% (174.8m / 1.04b)
NOPAT = 807.5m (EBIT 971.5m * (1 - 16.89%))
Current Ratio = 3.46 (Total Current Assets 1.25b / Total Current Liabilities 361.9m)
Debt / Equity = 0.09 (Debt 165.9m / totalStockholderEquity, last quarter 1.84b)
Debt / EBITDA = -0.67 (Net Debt -673.5m / EBITDA 999.8m)
Debt / FCF = -0.57 (Net Debt -673.5m / FCF TTM 1.18b)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 33.28% (Net Income 860.6m / Total Assets 2.49b)
RoE = 42.49% (Net Income TTM 860.6m / Total Stockholder Equity 2.03b)
RoCE = 45.56% (EBIT 971.5m / Capital Employed (Total Assets 2.49b - Current Liab 361.9m))
RoIC = 40.16% (NOPAT 807.5m / Invested Capital 2.01b)
WACC = 9.07% (E(12.5b)/V(12.7b) * Re(9.19%) + D(165.9m)/V(12.7b) * Rd(0.0%) * (1-Tc(0.17)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.66 | Cagr: -6.97%
[DCF] Terminal Value 75.67% ; FCFF base≈997.6m ; Y1≈1.14b ; Y5≈1.68b
[DCF] Fair Price = 93.44 (EV 22.5b - Net Debt -673.5m = Equity 23.2b / Shares 247.8m; r=9.07% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.02 | EPS CAGR: 87.14% | SUE: 0.50 | # QB: 0
Revenue Correlation: 96.27 | Revenue CAGR: 12.36% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.91 | Chg30d=+2.42% | Revisions=-29% | Analysts=11
EPS current Year (2026-12-31): EPS=3.57 | Chg30d=+1.01% | Revisions=-12% | GrowthEPS=+15.8% | GrowthRev=+10.0%
EPS next Year (2027-12-31): EPS=4.07 | Chg30d=+1.98% | Revisions=+0% | GrowthEPS=+14.1% | GrowthRev=+12.7%
[Analyst] Revisions Ratio: -19% (up=5, down=8)